87 related articles for article (PubMed ID: 23884051)
1. Immunotherapy to treat leukemia possibly ineffective for advanced disease.
Sinha G
J Natl Cancer Inst; 2013 Aug; 105(15):1068-9. PubMed ID: 23884051
[No Abstract] [Full Text] [Related]
2. [Immunotherapy and cell therapy for myeloid leukemia].
Yasukawa M
Nihon Rinsho; 2009 Oct; 67(10):1938-43. PubMed ID: 19860194
[TBL] [Abstract][Full Text] [Related]
3. Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells.
Riether C; Gschwend T; Huguenin AL; Schürch CM; Ochsenbein AF
Leukemia; 2015 Aug; 29(8):1781-5. PubMed ID: 25650092
[No Abstract] [Full Text] [Related]
4. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
[TBL] [Abstract][Full Text] [Related]
5. CD4+ T cells tumor specific response exists in L615 leukemia mice: adoptive transfer in combination with cyclophosphamide.
Zhang S; Zhang HJ; Wang HY; Wang Q; Li WF; Yu L
Exp Oncol; 2004 Jun; 26(2):156-7. PubMed ID: 15273668
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia.
Falkenburg JH; Smit WM; Willemze R
Immunol Rev; 1997 Jun; 157():223-30. PubMed ID: 9255633
[TBL] [Abstract][Full Text] [Related]
7. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.
de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H
J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791
[TBL] [Abstract][Full Text] [Related]
8. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
[TBL] [Abstract][Full Text] [Related]
9. Cloned helper and cytotoxic T lymphocytes as effector cells in adoptive immunotherapy of murine leukemia.
Bookman MA; Horak E; de Graaf PW
Prog Clin Biol Res; 1989; 288():141-9. PubMed ID: 2524069
[No Abstract] [Full Text] [Related]
10. Exciting times for our field and the Journal.
Humphries RK
Exp Hematol; 2011 Mar; 39(3):271. PubMed ID: 21277347
[No Abstract] [Full Text] [Related]
11. Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34+ selected allogeneic hematopoietic cell transplantation.
Bornhauser M; Thiede C; Babatz J; Schetelig J; Illmer T; Kiani A; Platzbecker U; Herr W; Rieber EP; Ehninger G; Schmitz M
Leukemia; 2006 Nov; 20(11):2055-7. PubMed ID: 16990776
[No Abstract] [Full Text] [Related]
12. Normal hematopoietic progenitor cells and malignant lymphohematopoietic cells show different susceptibility to direct cell-mediated MHC-non-restricted lysis by T cell receptor-/CD3-, T cell receptor gamma delta+/CD3+ and T cell receptor-alpha beta+/CD3+ lymphocytes.
Voogt PJ; Falkenburg JH; Fibbe WE; Veenhof WF; Hamilton M; Van Krimpen BA; Bolhuis RL
J Immunol; 1989 Mar; 142(5):1774-80. PubMed ID: 2521886
[TBL] [Abstract][Full Text] [Related]
13. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies.
Rosenfeld C; Cheever MA; Gaiger A
Leukemia; 2003 Jul; 17(7):1301-12. PubMed ID: 12835718
[TBL] [Abstract][Full Text] [Related]
14. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.
Ueda M; Joshi ID; Dan M; Uberti JP; Chou TH; Sensenbrenner LL; Lum LG
Transplantation; 1993 Aug; 56(2):351-6. PubMed ID: 8356589
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
[TBL] [Abstract][Full Text] [Related]
16. Efficient activation of LRH-1-specific CD8+ T-cell responses from transplanted leukemia patients by stimulation with P2X5 mRNA-electroporated dendritic cells.
Overes IM; Fredrix H; Kester MG; Falkenburg JH; van der Voort R; de Witte TM; Dolstra H
J Immunother; 2009; 32(6):539-51. PubMed ID: 19483655
[TBL] [Abstract][Full Text] [Related]
17. Autologous blood stem cell transplantation.
Goldman JM
Beitr Infusionsther; 1988; 21():317-21. PubMed ID: 2463002
[No Abstract] [Full Text] [Related]
18. [Polymorphic adhesion molecules mediating the graft-versus-leukemia effect].
Takami A; Nakao S
Rinsho Ketsueki; 2004 Mar; 45(3):183-8. PubMed ID: 15103930
[No Abstract] [Full Text] [Related]
19. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
Kessler JH; Bres-Vloemans SA; van Veelen PA; de Ru A; Huijbers IJ; Camps M; Mulder A; Offringa R; Drijfhout JW; Leeksma OC; Ossendorp F; Melief CJ
Leukemia; 2006 Oct; 20(10):1738-50. PubMed ID: 16932347
[TBL] [Abstract][Full Text] [Related]
20. Graft-vs-leukemia following bone marrow transplantation: a model of immunotherapy in man.
Butturini A; Bortin MM; Seeger RC; Gale RP
Prog Clin Biol Res; 1987; 244():371-90. PubMed ID: 3310000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
